Cost Is the Biggest Barrier to Elevidys Access — Here's How Providers Can Help

At approximately $3.2 million for a one-time treatment, Elevidys (Delandistrogene Moxeparvovec-rokl) represents one of the most expensive therapies in clinical medicine. For families navigating a Duchenne muscular dystrophy (DMD) diagnosis, the financial complexity of accessing this gene therapy can be as daunting as the disease itself.

As a provider, you play a critical role in connecting eligible patients with the financial resources that make Elevidys treatment possible. This guide outlines the manufacturer support programs, insurance navigation strategies, and practical workflows that can help your patients access this therapy without being crushed by the cost burden.

What Patients Are Paying

Understanding the financial landscape is essential for counseling families:

• Wholesale acquisition cost (WAC): Approximately $3.2 million for the one-time infusion
• No generic or biosimilar available: Elevidys is a biologic gene therapy with no alternative formulation. There is no lower-cost equivalent.
• Out-of-pocket exposure varies widely: Depending on insurance type, families may face significant cost-sharing through copays, coinsurance, or deductible requirements — even with coverage approval. For a $3.2 million treatment, even a small coinsurance percentage translates to enormous out-of-pocket costs.
• Indirect costs: Families also face travel expenses to specialized treatment centers, lodging during the treatment and monitoring period, lost wages for caregivers, and costs associated with the required corticosteroid regimen and follow-up care.

The reality is that without significant financial support, very few families could access Elevidys purely through their out-of-pocket resources. The support ecosystem described below is essential to treatment access.

Manufacturer Savings Programs: SareptAssist

Sarepta Therapeutics operates SareptAssist, a comprehensive patient support program that serves as the primary financial navigation resource for Elevidys. Understanding and leveraging this program should be your first step when prescribing Elevidys.

What SareptAssist Provides

• Insurance navigation: Dedicated case managers help navigate the prior authorization process, which is extensive for a $3.2 million gene therapy. They assist with gathering required documentation, submitting authorization requests, and managing appeals if initial requests are denied.
• Benefits verification: SareptAssist verifies insurance coverage and identifies the patient's expected cost-sharing obligations before treatment begins.
• Copay and coinsurance support: For commercially insured patients, SareptAssist may provide financial assistance to reduce out-of-pocket costs associated with the treatment.
• Treatment logistics coordination: The program helps coordinate product shipping to the treatment center, scheduling, and other logistical requirements specific to Elevidys administration.
• Connections to additional resources: SareptAssist connects families with independent charitable foundations, patient advocacy organizations, and other financial assistance programs when additional support is needed.

How to Enroll Patients

Contact SareptAssist at 1-888-SAREPTA (1-888-727-3782) or through Sarepta's healthcare provider portal. Enrollment should begin as early as possible in the treatment consideration process — ideally at the point when genetic testing confirms eligibility, before formal prescribing. Early enrollment allows the prior authorization process to begin while clinical evaluation continues.

Insurance Navigation Strategies

Prior authorization for Elevidys is among the most complex in medicine. Here are strategies to improve approval rates:

Documentation Best Practices

• Genetic test results: Include complete genetic testing documentation confirming the specific DMD gene mutation and that it is amenable to Elevidys treatment. Ensure exons 8 and 9 are not affected.
• Ambulatory status confirmation: Provide detailed functional assessments (North Star Ambulatory Assessment, timed function tests, 6-minute walk test) documenting that the patient is ambulatory.
• Age verification: Confirm the patient is 4 years of age or older.
• Letter of medical necessity: Write a detailed letter explaining why Elevidys is medically necessary for this specific patient, citing the progressive nature of DMD, the patient's current functional status, and the time-sensitive nature of treatment (patients must be ambulatory).
• Peer-reviewed literature: Include relevant clinical trial data and publications supporting Elevidys efficacy.

Handling Denials and Appeals

• First-level appeal: Most initial denials are administrative rather than clinical. Review the denial reason carefully — common issues include incomplete documentation, incorrect coding, or missing genetic test details.
• Peer-to-peer review: Request a peer-to-peer conversation with the insurance company's medical director. Having the prescribing neuromuscular specialist directly discuss the case often resolves clinical denials.
• External review: If internal appeals are exhausted, patients have the right to an independent external review in most states.
• SareptAssist support: Leverage SareptAssist's experienced case managers throughout the appeals process. They have extensive experience navigating Elevidys-specific coverage challenges.

Additional Financial Resources

Patient Advocacy Organizations

Several DMD-focused organizations provide financial assistance or can connect families with resources:

• Parent Project Muscular Dystrophy (PPMD) — Offers family support services, care center connections, and financial assistance resources
• CureDuchenne — Provides grants, support services, and financial navigation for DMD families
• Muscular Dystrophy Association (MDA) — Operates a Care Center Network and provides financial assistance for equipment, travel, and treatment-related costs

Charitable Foundations

Independent charitable foundations that support rare disease patients may help with Elevidys-related costs. SareptAssist can identify specific foundations accepting applications for gene therapy financial assistance.

State and Federal Programs

• Medicaid: For families who qualify, Medicaid coverage of Elevidys varies by state but typically covers FDA-approved treatments with appropriate authorization.
• Children's Health Insurance Program (CHIP): Similar to Medicaid, coverage varies by state.
• Supplemental Security Income (SSI): Families of children with DMD may qualify for SSI, which can help cover indirect costs of treatment.

Generic Alternatives and Therapeutic Substitution

There are no generic or biosimilar alternatives to Elevidys. As an AAV-based gene therapy, it cannot be substituted with a lower-cost equivalent.

However, for patients who are not eligible for Elevidys or cannot access it, alternative DMD treatments exist that may be more accessible:

• Deflazacort (Emflaza) — A corticosteroid approved specifically for DMD. Lower cost than gene therapy but requires ongoing daily dosing.
• Exon-skipping therapies (Eteplirsen/Exondys 51, Casimersen/Amondys 45, Viltolarsen/Viltepso) — For patients with specific exon mutations. These require weekly IV infusions and have their own prior authorization challenges, but costs are distributed over time rather than concentrated in a single multi-million-dollar treatment.

For a complete comparison of alternative treatments, see our guide to Elevidys alternatives. Providers can also review our provider-specific shortage update and guide to finding Elevidys in stock.

Building Cost Conversations into Your Workflow

Integrating financial discussions into the treatment planning process improves patient outcomes and reduces access barriers:

When to Start the Conversation

Begin discussing cost and financial support at the same time you discuss Elevidys as a treatment option — not after the decision has been made. For many families, understanding that a robust financial support system exists is essential to even considering the treatment.

What to Cover

• Frame the cost honestly: "Elevidys is approximately $3.2 million for a one-time treatment, but very few families pay anything close to that out of pocket. There are programs specifically designed to help."
• Introduce SareptAssist early: "We'll enroll you in Sarepta's patient support program right away. They have case managers who specialize in navigating insurance and financial assistance for Elevidys."
• Set timeline expectations: "The insurance authorization process can take weeks to months. Starting early gives us the best chance of a smooth approval."
• Address indirect costs: "There may be costs related to travel, lodging, and time off work. Let's identify resources that can help with those too."

Designate a Financial Navigation Point Person

If your practice or institution has a financial counselor, social worker, or patient navigator, involve them from the beginning. For institutions that serve as Elevidys treatment centers, having a dedicated team member who understands the SareptAssist process and insurance requirements can dramatically improve access timelines.

Document Everything

Thorough clinical documentation from the outset reduces delays and denial rates. Make prior authorization a clinical priority, not an afterthought.

Final Thoughts

The $3.2 million price of Elevidys creates real access barriers, but the combination of SareptAssist, insurance navigation strategies, advocacy organization support, and proactive provider engagement can make treatment accessible for eligible patients. As a provider, your role in initiating these conversations early, providing thorough documentation, and connecting families with resources is as important as the clinical decision to prescribe.

For more provider resources, visit Medfinder for Providers to access tools for locating specialty medications and supporting patient access.